A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

The US Shifts Focus to Development of Anti-Viral Pills to Treat COVID-19


The United States Department of Health and Human Services is spending more than $3 billion to develop anti-viral pills to treat COVID-19. The significant financial commitment will support clinical trials of three potentially viable medications to address the illness caused by the novel coronavirus. Thus far, the only antiviral treatment approved by the Food and Drug Administration to treat COVID-19 is remdesivir, whose results have been underwhelming. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy